ReviewJournal of obesity & metabolic syndrome2025
Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated by Diabetes: Pathophysiology and Emerging Therapies.
Review in Journal of obesity & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The cholesterol, high-density lipoprotein, and glucose index and its derived indices predict cardiometabolic multimorbidity development and progression in metabolic dysfunction-associated steatotic liver disease individuals: a prospective cohort study.Cardiovascular diabetology · 2026Article
- Biomarkers in Diabetic Kidney Disease: Early Detection, Prognostic Assessment, and Integration with Multi-Omics Signatures.Life (Basel, Switzerland) · 2026Review
- Mitochondrial Dysfunction in Metabolic-Syndrome-Related MASLD/MASH: Metabolic Mechanisms and Therapeutic Perspectives.Metabolites · 2026Review
- Interplay between MASLD, obesity and type 2 diabetes: epidemiology, shared pathways and clinical implications.BMJ open gastroenterology · 2026Review
- Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics.BMJ open gastroenterology · 2026Review
- Research Progress on Downstream Mechanisms of Glucose Metabolic Reprogramming and Its Role in the Occurrence and Progression of Type 2 Diabetes Mellitus.Biomedicines · 2026Review
- Ibero-American position statement on therapeutic recommendations for the preventive management of cardiovascular complications in latin-American patients with type 2 diabetes mellitus: consensus of the prevention council of the inter-American society of cardiology (SIAC-PREVENT).Diabetology & metabolic syndrome · 2026Review
- Review
- Association of cholesterol, high-density lipoprotein and glucose (CHG) index with mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) adults: results from two prospective cohorts.Cardiovascular diabetology · 2026Article
- Metabolic dysfunction-associated steatotic liver disease as a systemic disorder: extrahepatic manifestations and the need for data-driven phenotyping.Frontiers in endocrinology · 2026Review
- Research progress on the pathophysiological mechanisms of pioglitazone-induced heart failure: a review.Frontiers in cardiovascular medicine · 2026Review
- Convergent Metabolic Pathways in MASH Therapeutics: An AMPK-Centric Analysis.Journal of cellular and molecular medicine · 2026Review
- Loss of immunometabolic adaptability in MASH: gut-derived signals drive macrophage reprogramming and fibrosis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a liver manifestation of diabetes that is often associated with obesity and insulin resistance, with hyperglycemia worsening its progression. Recent studies have shown a bidirectional relationship between MASLD and diabetes: MASLD contributes to insulin resistance, and hyperglycemia accelerates the progression of MASLD to metabolic dysfunction-associated steatohepatitis (MASH). Hepatokines upregulated by overnutrition and hyperglycemia are implicated in the link between liver steatosis and insulin resistance in skeletal muscle, highlighting inter-organ crosstalk in the progression of both MASLD and diabetes. In individuals with diabetes, hyperglycemia and free fatty acid influx promote
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.